吉西他滨联合白蛋白结合型紫杉醇联合或不联合羟氯喹对晚期胰腺癌患者的疗效:一项2期随机临床试验
这项开放标签2期随机试验在112例初治转移性或晚期胰腺导管腺癌患者中比较吉西他滨联合白蛋白结合型紫杉醇(GA)加或不加羟氯喹(HCQ)的疗效。12个月总生存率HCQ组41%、非HCQ组49%,未改善主要终点;总缓解率HCQ组38.2% vs 非HCQ组21.1%(P=0.047)。
要点
- 在GA基础上加用HCQ未改善12个月总生存率(HCQ组41% vs 非HCQ组49%)。
- 总缓解率HCQ组38.2%(n=21)vs 非HCQ组21.1%(n=12),P=0.047。
- HCQ组3/4级中性粒细胞减少42.6% vs 非HCQ组22.6%,另见疲乏、恶心、视觉改变等。
核心结论
- 在GA基础上加用HCQ阻断自噬未改善12个月总生存率这一主要终点。
- 这些数据不支持在无生物标志物的情况下常规使用GA联合HCQ治疗转移性胰腺癌。
- HCQ组总缓解率的改善可能提示HCQ在局部晚期场景中的作用,即肿瘤缓解可能允许切除。
研究设计与样本
- 开放标签、2期随机临床试验,于2013年3月18日至2017年11月16日在宾夕法尼亚大学、HonorHealth和约翰斯·霍普金斯大学开展。
- 纳入112例既往未治疗的转移性或晚期胰腺导管腺癌患者,ECOG体能状态为0或1,骨髓和器官功能充足。
- 患者按1:1随机接受GA联合或不联合HCQ;所有患者接受标准剂量GA,HCQ组持续口服600 mg每日两次。
- 所有疗效分析均在意向治疗人群中进行。
主要发现
- 共纳入112例患者(45例女性,67例男性;中位年龄65岁,范围43-86岁);55例随机至GA联合HCQ组,57例随机至GA组。
- 12个月总生存率HCQ组为41%(95%CI 27%-53%),非HCQ组为49%(95%CI 35%-61%)。
- 中位无进展生存期HCQ组为5.7个月(95%CI 4.0-9.3个月),非HCQ组为6.4个月(95%CI 4.5-7.6个月)。
- 中位总生存期HCQ组为11.1个月(95%CI 9.0-14.2个月),非HCQ组为12.1个月(95%CI 9.3-15.5个月)。
- 总缓解率HCQ组为38.2%(n=21),非HCQ组为21.1%(n=12)(P=0.047)。
关键数值与推荐
- 主要终点为12个月总生存率,HCQ组41%(95%CI 27%-53%)vs 非HCQ组49%(95%CI 35%-61%)。
- 总缓解率HCQ组38.2%(n=21)vs 非HCQ组21.1%(n=12),P=0.047。
- 中位总生存期HCQ组11.1个月(95%CI 9.0-14.2个月)vs 非HCQ组12.1个月(95%CI 9.3-15.5个月)。
临床怎么用
- 作者认为,这些数据不支持在无生物标志物的情况下常规使用GA联合HCQ治疗转移性胰腺癌。
- 作者提出,HCQ组总缓解率的改善可能提示HCQ在局部晚期场景中的作用,即肿瘤缓解可能允许切除。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Autophagy is a mechanism of treatment resistance to chemotherapy that has a role in the maintenance of pancreatic cancer. Hydroxychloroquine sulfate (HCQ) is an inhibitor of autophagy that inhibits the fusion of the autophagosome to the lysosome. OBJECTIVE: To determine whether HCQ improves overall survival at 1 year in combination with gemcitabine hydrochloride and nab-paclitaxel (GA) among patients with metastatic pancreatic cancer. DESIGN, SETTING, AND PARTICIPANTS: Open-label, phase 2 randomized clinical trial conducted between March 18, 2013, and November 16, 2017, at the University of Pennsylvania, HonorHealth, and The Johns Hopkins University among 112 patients with previously untreated metastatic or advanced pancreatic ductal adenocarcinoma, Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate marrow and organ function. All efficacy analyses were performed for the intention-to-treat population. INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive GA with or without HCQ. All patients received standard doses of GA, and those randomized to receive HCQ were treated continuously with 600 mg orally twice daily. MAIN OUTCOME AND MEASURE: Overall survival at 1 year. RESULTS: A total of 112 patients (45 women and 67 men; median age, 65 years; range, 43-86 years) were enrolled; 55 were randomized to receive GA plus HCQ, and 57 to receive GA. Overall survival at 12 months was 41% (95% CI, 27%-53%) in the HCQ group and 49% (95% CI, 35%-61%) in the non-HCQ group. Median progression-free survival was 5.7 months (95% CI, 4.0-9.3 months) in the HCQ group and 6.4 months (95% CI, 4.5-7.6 months) in the non-HCQ group. Median overall survival was 11.1 months (95% CI, 9.0-14.2 months) in the HCQ group and 12.1 months (95% CI, 9.3-15.5 months) in the non-HCQ group. Overall response rate was 38.2% (n = 21) in the HCQ group and 21.1% (n = 12) in the non-HCQ group (P = .047). Treatment-related grade 3 or 4 adverse events that differed between the HCQ and non-HCQ groups were neutropenia (23 of 54 [42.6%] vs 12 of 53 [22.6%]), anemia (2 of 54 [3.7%] vs 9 of 53 [17.0%]), fatigue (4 of 54 [7.4%] vs 0), nausea (5 of 54 [9.3%] vs 0), peripheral neuropathy (7 of 54 [13.0%] vs 3 of 53 [5.7%]), visual changes (3 of 54 [5.6%] vs 0), and neuropsychiatric symptoms (3 of 54 [5.6%] vs 0). CONCLUSIONS AND RELEVANCE: The addition of HCQ to block autophagy did not improve the primary end point of overall survival at 12 months. These data do not support the routine use of GA plus HCQ for metastatic pancreatic cancer in the absence of a biomarker. However, improvement seen in the overall response rate with HCQ may indicate a role for HCQ in the locally advanced setting, where tumor response may permit resection. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01506973.
引用
- Karasic TB, O'Hara MH, Loaiza-Bonilla A, et al. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 31120501. doi:10.1001/jamaoncol.2019.0684
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。